UCB Trading (Shanghai) Co., Ltd.

Primary objective: To compare the efficacy of Bimekizumab administered subcutaneously for 16 weeks with placebo in the treatment of moderate to severe plaque PSO study subjects. Secondary objectives: To evaluate the efficacy of Bimekizumab compared with placebo at 4 weeks: achieving PASI75 response; To evaluate the efficacy of Bimekizumab compared with placebo at 16 weeks: achieving complete clearance (PASI100); To evaluate the effect of Bimekizumab compared with placebo at 16 weeks on pruritus, pain and scaling as assessed by PSD (P-SIM) response; To evaluate the safety of Bimekizumab during the 16-week treatment period.

Primary objective: To evaluate the long-term safety and tolerability of rozanolixizumab treatment (maintenance only group); Secondary objectives: To evaluate the long-term clinical effectiveness of rozanolixizumab treatment (maintenance only group) To evaluate the effect of rozanolixizumab on study participants' perceived symptoms To evaluate the pharmacodynamic (PD) effects of rozanolixizumab (maintenance only group) To evaluate the reduction in the use of steroids and other concomitant ITP medications

Primary objective: To evaluate the effect of 6-month treatment with Romosozumab on the % change of lumbar spine BMD in Chinese postmenopausal women with osteoporosis compared with placebo Secondary objective of the double-blind controlled period: To evaluate the effect of 6-month treatment with Romosozumab on the % change of total hip and femoral neck BMD in Chinese postmenopausal women with osteoporosis compared with placebo Safety objective of the double-blind controlled period: To summarize the safety and tolerability of Romosozumab in the treatment of Chinese postmenopausal women with osteoporosis compared with placebo